Showing 15,221 - 15,240 results of 104,189 for search '(( 50 ((nn decrease) OR (we decrease)) ) OR ( 5 ((step decrease) OR (a decrease)) ))', query time: 1.74s Refine Results
  1. 15221

    DataSheet_1_The prevalence of diabetes and thyroid related autoantibodies in Sri Lankan children with type 1 diabetes and their unaffected siblings – The utility of a new screening... by Navoda Atapattu (14570081)

    Published 2023
    “…</p>Results<p>The median age (IQR) of 235 T1D children and 252 unaffected siblings was 11 (8.4, 13.2) and 9 (5.4, 14.9) years respectively, and the duration of T1D was 23 (7, 54) months. (1) T1D children (a) 79.1% were 3-Screen positive; (b) all 3-Screen positives were individual antibody positive (GADA in 74%; IA-2A 31.1%; ZnT8A 38.7%); (c) and were younger (p=0.01 vs 3-Screen negatives); (d) multiple autoantibodies were present in 45.1%; (e) IA-2A (p=0.002) and ZnT8A (p=0.006) prevalence decreased with T1D duration. …”
  2. 15222
  3. 15223

    Nonequilibrium Arrhythmic States and Transitions in a Mathematical Model for Diffuse Fibrosis in Human Cardiac Tissue by Rupamanjari Majumder (128411)

    Published 2012
    “…Our study of a single myocyte-fibroblast (MF) composite, with a single myocyte coupled to fibroblasts via a gap-junctional conductance , reveals five qualitatively different responses for this composite. …”
  4. 15224
  5. 15225
  6. 15226
  7. 15227

    C9orf72 and SMCR8 form a stable protein complex. by Janet Ugolino (3359054)

    Published 2016
    “…Immunoblot analysis of SMCR8 KO HAP1 cell lysates shows a decrease in C9orf72 levels compared with control HAP1 cells. …”
  8. 15228
  9. 15229
  10. 15230

    Table 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

    Published 2025
    “…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”
  11. 15231

    Image 1_Multi-omics-based phenotyping of AFG3L2-mutant lymphoblasts determines key factors of a pathophysiological interplay between mitochondrial vulnerability and neurodegenerati... by Menekse Oeztuerk (20756606)

    Published 2025
    “…Mutations in AFG3L2 are implicated in a spectrum of diseases, including spinocerebellar ataxia type 28 (SCA28) and spastic ataxia 5 (SPAX5), as well as other systemic conditions. …”
  12. 15232

    Table_5_Depletion of tet2 results in age-dependent changes in DNA methylation and gene expression in a zebrafish model of myelodysplastic syndrome.xlsx by Yaseswini Neelamraju (4509259)

    Published 2023
    “…The gene encoding ten-eleven translocation 2 (tet2), a dioxygenase enzyme that catalyzes the conversion of 5-methylcytosine (5mC) to 5-hydroxymethylcytosine, is a recurrently mutated tumor suppressor gene in MDS and other myeloid malignancies. …”
  13. 15233
  14. 15234
  15. 15235
  16. 15236

    Comparison of the effects of several 5-HT receptor antagonists on the plasma concentrations of metabolites and insulin, following 5-HT injection in sheep and mice. by Hitoshi Watanabe (519631)

    Published 2014
    “…</p>b<p>5-HT: serotonin; Me: methysergide; Ke: ketanserin; SB-26: SB-269970; SB-20: SB-204070; Ro: Ro 04-6790; I: increase; D: decrease; N: no change; +: effective in blocking the effect of 5-HT; −: ineffective in blocking the effect of 5-HT.…”
  17. 15237

    Data Sheet 1_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  18. 15238

    Data Sheet 2_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  19. 15239

    Data Sheet 3_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.pdf by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”
  20. 15240

    Data Sheet 4_Prevalence and duration of clinical symptoms of pediatric long COVID: findings from a one-year prospective study.docx by Vita Perestiuk (22290208)

    Published 2025
    “…Multivariable logistic regression showed that older age was significantly associated with a higher risk of decreased physical activity (OR = 1.51, p = 0.038), lack of energy (OR = 2.00, p = 0.003), neurological symptoms (OR = 1.86, p = 0.007), headache (OR = 4.51, p = 0.000), memory impairment (OR = 5.12, p = 0.000), difficulty communicating (OR = 4.28, p = 0.000), difficulty concentrating (OR = 2.74, p = 0.001), cardiological symptoms (OR = 2.34, p = 0.022), sensory symptoms (OR = 2.66, p = 0.011), and dizziness (OR = 10.02, p = 0.034). …”